Catalent, the contract drug maker known for manufacturing COVID-19 vaccines, said on Monday it would buy gummy vitamins maker Bettera Holdings for $1bn in cash to expand in the nutritional supplements market.
Texas-based Bettera makes vitamins, supplements and minerals delivered in the form of gummies, lozenges and chewables. It is backed by private investment firm Highlander Partners LP.
Chewable forms of vitamins, such as gummies, are gaining popularity, especially among people who find swallowing pills difficult, and the market is expected to reach $9.3bn by 2026, according to a report by Allied Market Research.
Subscribe to our Newsletter to increase your edge. Don’t worry about the news anymore, through our newsletter you’ll receive weekly access to what is happening. Join 120,000 other PE professionals today.
Catalent, which has been involved in the manufacturing of COVID-19 vaccines, including those from Moderna, AstraZeneca and Johnson & Johnson, makes softgel capsules which are easy to consume and come in a variety of flavors and sweeteners.
Centerview Partners LLC was the financial adviser to Catalent on the deal, which is expected to close before the end of 2021.
The Wall Street Journal first reported the deal.
Source: WBHL
Can’t stop reading? Read more
Blackstone taps bond market as private credit BDCs end issuance drought
Blackstone taps bond market as private credit BDCs end issuance drought Blackstone's private...
EQT raises the stakes with revised $12.3bn bid for Intertek
EQT raises the stakes with revised $12.3bn bid for Intertek EQT has tabled an improved takeover...
Temasek’s Azalea bets on evergreen structure to democratise private equity access
Temasek's Azalea bets on evergreen structure to democratise private equity access Azalea, a unit...